We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
Read MoreHide Full Article
Key Takeaways
QIAGEN launched QIA Agent to simplify experiment planning and product support workflows.
QGEN's AI platform connects research tools, protocols and ordering support in one interface.
QIAGEN said QIA Agent can improve lab productivity and accelerate scientific decisions.
QIAGEN (QGEN - Free Report) recently launched QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify products, access technical information and manage ordering support through a single conversational interface.
Management noted that QIA Agent expands the company’s broader AI-enabled digital ecosystem strategy by embedding conversational AI directly into customer workflows. The launch is expected to strengthen customer engagement and improve workflow efficiency across laboratories worldwide.
Likely Trend of QGEN Stock Following the News
Shares of QGEN have gained 2.5% since the announcement on Wednesday. In the year-to-date period, shares of the company have lost 25.9% compared with the industry’s 2.8% decline. However, the S&P 500 has risen 8.1% during the same timeframe.
The launch of QIA Agent is likely to strengthen QIAGEN’s long-term growth prospects by deepening customer engagement across its Sample to Insight workflows and expanding its digital ecosystem capabilities. By integrating AI-driven scientific guidance, product discovery and operational support into a single conversational platform, QIAGEN can improve customer retention, increase cross-selling opportunities and drive higher utilization of its consumables and workflow solutions.
The platform also positions the company to capitalize on the growing adoption of AI-enabled laboratory workflows, while enhancing operational efficiency and differentiating QIAGEN’s offerings in the competitive life sciences tools market.
QGEN currently has a market capitalization of $7.06 billion.
Image Source: Zacks Investment Research
More on the QGEN’s QIA Agent
QIA Agent platform connects multiple elements of QIAGEN’s Sample to Insight ecosystem through a single conversational interface, enabling researchers to plan experiments, identify suitable products, access technical documentation and manage ordering-related tasks more efficiently. The company noted that QIA Agent is accessible directly through its website and can be used both with and without login credentials, allowing broader access while offering more personalized experiences for registered users.
Management highlighted that the launch comes at a time when laboratories are dealing with increasing scientific complexity, expanding workflow choices and rapidly growing data volumes. QIA Agent leverages conversational AI to help reduce the time researchers spend searching across multiple systems and resources. The platform combines product information, protocols, technical documentation and support tools into one integrated interface, enabling quicker and more informed decision-making. Logged-in users can additionally access account-specific information, including pricing, order history and customized support, helping improve convenience and workflow continuity. The company currently has more than 260,000 registered users on its My QIAGEN platform, providing an established customer base for adoption of the new AI-driven tool.
The platform also integrates with several existing QIAGEN digital services, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center, creating a more seamless experience from experiment planning to post-purchase support. Researchers can use QIA Agent to check product availability, track orders and access workflow guidance without switching between multiple systems.
Per management, the launch forms part of QIAGEN’s broader strategy to embed AI and digital technologies across its customer-facing ecosystem. While currently intended for research use only and not diagnostic applications, the company believes the platform can help laboratories improve productivity, save time and accelerate scientific decision-making through easier access to relevant information and workflow support.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global artificial intelligence in healthcare market size was estimated at $36.67 billion in 2025 and is projected to reach $505.59 billion by 2033, expanding at a CAGR of 38.90%.
The key factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy and better patient outcomes.
Other News
QIAGEN recently announced a collaboration with NVIDIA to advance AI-driven drug discovery by integrating the latter’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases. Management noted that the collaboration will initially support pilot programs with select pharmaceutical and biotechnology partners before broader commercial availability in future stages following validation.
Also, QGEN recently announced plans to launch a new fully automated Sample to Insight workflow and an AI-enabled risk stratification tool to advance QuantiFERON latent tuberculosis testing, with both targeted for launch in late 2027. The company also plans to introduce an AI-enabled risk stratification tool designed to support clinical decision-making by helping identify patients at higher risk of TB progression.
QGEN’s Zacks Rank & Key Picks
Currently, QGEN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
Key Takeaways
QIAGEN (QGEN - Free Report) recently launched QIA Agent, an AI-powered digital assistant designed to simplify how researchers plan experiments, identify products, access technical information and manage ordering support through a single conversational interface.
Management noted that QIA Agent expands the company’s broader AI-enabled digital ecosystem strategy by embedding conversational AI directly into customer workflows. The launch is expected to strengthen customer engagement and improve workflow efficiency across laboratories worldwide.
Likely Trend of QGEN Stock Following the News
Shares of QGEN have gained 2.5% since the announcement on Wednesday. In the year-to-date period, shares of the company have lost 25.9% compared with the industry’s 2.8% decline. However, the S&P 500 has risen 8.1% during the same timeframe.
The launch of QIA Agent is likely to strengthen QIAGEN’s long-term growth prospects by deepening customer engagement across its Sample to Insight workflows and expanding its digital ecosystem capabilities. By integrating AI-driven scientific guidance, product discovery and operational support into a single conversational platform, QIAGEN can improve customer retention, increase cross-selling opportunities and drive higher utilization of its consumables and workflow solutions.
The platform also positions the company to capitalize on the growing adoption of AI-enabled laboratory workflows, while enhancing operational efficiency and differentiating QIAGEN’s offerings in the competitive life sciences tools market.
QGEN currently has a market capitalization of $7.06 billion.
Image Source: Zacks Investment Research
More on the QGEN’s QIA Agent
QIA Agent platform connects multiple elements of QIAGEN’s Sample to Insight ecosystem through a single conversational interface, enabling researchers to plan experiments, identify suitable products, access technical documentation and manage ordering-related tasks more efficiently. The company noted that QIA Agent is accessible directly through its website and can be used both with and without login credentials, allowing broader access while offering more personalized experiences for registered users.
Management highlighted that the launch comes at a time when laboratories are dealing with increasing scientific complexity, expanding workflow choices and rapidly growing data volumes. QIA Agent leverages conversational AI to help reduce the time researchers spend searching across multiple systems and resources. The platform combines product information, protocols, technical documentation and support tools into one integrated interface, enabling quicker and more informed decision-making. Logged-in users can additionally access account-specific information, including pricing, order history and customized support, helping improve convenience and workflow continuity. The company currently has more than 260,000 registered users on its My QIAGEN platform, providing an established customer base for adoption of the new AI-driven tool.
The platform also integrates with several existing QIAGEN digital services, including the Experiment Configurator, Order Status Checker, Product Availability Checker and Help Center, creating a more seamless experience from experiment planning to post-purchase support. Researchers can use QIA Agent to check product availability, track orders and access workflow guidance without switching between multiple systems.
Per management, the launch forms part of QIAGEN’s broader strategy to embed AI and digital technologies across its customer-facing ecosystem. While currently intended for research use only and not diagnostic applications, the company believes the platform can help laboratories improve productivity, save time and accelerate scientific decision-making through easier access to relevant information and workflow support.
Industry Prospects Favoring the Market
Per a report by Grand View Research, the global artificial intelligence in healthcare market size was estimated at $36.67 billion in 2025 and is projected to reach $505.59 billion by 2033, expanding at a CAGR of 38.90%.
The key factor driving market growth is the increasing demand in the healthcare sector for enhanced efficiency, accuracy and better patient outcomes.
Other News
QIAGEN recently announced a collaboration with NVIDIA to advance AI-driven drug discovery by integrating the latter’s accelerated computing and BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases. Management noted that the collaboration will initially support pilot programs with select pharmaceutical and biotechnology partners before broader commercial availability in future stages following validation.
Also, QGEN recently announced plans to launch a new fully automated Sample to Insight workflow and an AI-enabled risk stratification tool to advance QuantiFERON latent tuberculosis testing, with both targeted for launch in late 2027. The company also plans to introduce an AI-enabled risk stratification tool designed to support clinical decision-making by helping identify patients at higher risk of TB progression.
QGEN’s Zacks Rank & Key Picks
Currently, QGEN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 29.4%. Revenues of $37 million missed the Zacks Consensus Estimate by 9.3%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
PACB’s earnings are estimated to decline at a rate of 12.2% against the industry’s 16.9% growth in 2027. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 29.76%.
Globus Medical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted earnings per share of $1.12, which outpaced the Zacks Consensus Estimate by 21.7%. Revenues of $760 million surpassed the Zacks Consensus Estimate by 4%.
GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 26.26%.
Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which beat the Zacks Consensus Estimate by 35.71%. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.
BDSX has an estimated earnings growth rate of 36% for 2026 compared with the industry’s 13.4% rise. The company beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 25.56%.